CEL-SCI Hires VP Of Manufacturing/Facilities And Commercial Ops
CEL-SCI Corporation (NYSE Amex: CVM), a late-stage oncology company and a developer of vaccines and therapeutics for the treatment of infectious diseases , appointed Todd S. Burkhart as Vice President of Manufacturing/Facilities and Commercial Operations for its manufacturing facility this week. Mr. Burkhart has over 30 years of experience in the manufacture and process development of biologicals, medical devices and other Active Pharmaceutical Ingredients (APIs).
“We are pleased to have been able to attract to our team such an accomplished executive, with deep experience and expertise in all facets of the manufacturing process for biologics and other drugs” said Geert Kersten, Chief Executive Officer of CEL-SCI. “This hire represents another step CEL-SCI has taken in order to increase the likelihood of a successful outcome of its global pivotal Phase III study of Multikine® for the treatment of head and neck cancer.”
During his distinguished career in the Pharmaceutical and Biopharmaceutical Industry and prior to joining CEL-SCI, Mr. Burkhart has been responsible for all aspects of GMP manufacturing and operations including production, materials controls and facilities maintenance. In addition he has extensive experience in the design of manufacturing facilities meeting FDA GMP requirements. Mr. Burkhart has also been involved in the building and/or running a number of major pharmaceutical facilities at companies such as Cephalon, Human Genome Sciences and Univax Biologics.
